Premium
Low levels of lymphocyte MDR1 gene expression during early renal transplantation in patients treated with tacrolimus
Author(s) -
Becquemont Laurent,
Camus Maryse,
Kriaa Faical,
Barbu Véronique,
Charpentier Bernard,
Jaillon Patrice
Publication year - 2000
Publication title -
fundamental and clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.655
H-Index - 73
eISSN - 1472-8206
pISSN - 0767-3981
DOI - 10.1111/j.1472-8206.2000.tb00020.x
Subject(s) - tacrolimus , lymphocyte , transplantation , medicine , gene expression , immunology , calcineurin , urology , biology , gene , genetics
— P‐glycoprotein (P‐gp) is a membrane efflux pump increasing the transport of drugs such as tacrolimus out of the cells. The aim of the study was to determine the kinetics of lymphocyte P‐gp expression in patients treated with tacrolimus during the first 3 months following renal transplantation. Lymphocyte MDR1 gene expression was measured by semi‐quantitative RT‐PCR a few hours before transplantation, 3 weeks and 3 months after the graft. Lymphocyte MDR1 gene expression was low in all the 10 patients compared to 10 healthy volunteers: 0.30 ± 0.07 arbitrary units (patients) vs. 1.74 ± 0. 55 (healthy volunteers) ( P = 0.0002). MDR1 gene expression decreased among the patients during the study: 0.28 ± 0.12 (3 weeks later) and 0.12 ± 0.09 (3 months later) ( P = 0.006). We can conclude that lymphocyte MDR1 gene expression among patients before renal transplantation is low and remains low during the first 3 months following the graft.